TY - JOUR
T1 - Assessment of Murine Colon Inflammation Using Intraluminal Fluorescence Lifetime Imaging
AU - Alfonso-Garcia, Alba
AU - Cevallos, Stephanie A.
AU - Lee, Jee Yon
AU - Li, Cai
AU - Bec, Julien
AU - Bäumler, Andreas J.
AU - Marcu, Laura
N1 - Funding Information:
Funding: Work in AJB’s laboratory was supported by NIH grant AI112445 and CCFA Senior Research Award 650976.
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Inflammatory bowel disease (IBD) is typically diagnosed by exclusion years after its onset. Current diagnostic methods are indirect, destructive, or target overt disease. Screening strategies that can detect low-grade inflammation in the colon would improve patient prognosis and alleviate associated healthcare costs. Here, we test the feasibility of fluorescence lifetime imaging (FLIm) to detect inflammation from thick tissue in a non-destructive and label-free approach based on tissue autofluorescence. A pulse sampling FLIm instrument with 355 nm excitation was coupled to a rotating side-viewing endoscopic probe for high speed (10 mm/s) intraluminal imaging of the entire mucosal surface (50–80 mm) of freshly excised mice colons. Current results demonstrate that tissue autofluorescence lifetime was sensitive to the colon anatomy and the colonocyte layer. Moreover, mice under DSS-induced colitis and 5-ASA treatments showed changes in lifetime values that were qualitatively related to inflammatory markers consistent with alterations in epithelial bioenergetics (switch between β-oxidation and aerobic glycolysis) and physical structure (colon length). This study demonstrates the ability of intraluminal FLIm to image mucosal lifetime changes in response to inflammatory treatments and supports the development of FLIm as an in vivo imaging technique for monitoring the onset, progression, and treatment of inflammatory diseases.
AB - Inflammatory bowel disease (IBD) is typically diagnosed by exclusion years after its onset. Current diagnostic methods are indirect, destructive, or target overt disease. Screening strategies that can detect low-grade inflammation in the colon would improve patient prognosis and alleviate associated healthcare costs. Here, we test the feasibility of fluorescence lifetime imaging (FLIm) to detect inflammation from thick tissue in a non-destructive and label-free approach based on tissue autofluorescence. A pulse sampling FLIm instrument with 355 nm excitation was coupled to a rotating side-viewing endoscopic probe for high speed (10 mm/s) intraluminal imaging of the entire mucosal surface (50–80 mm) of freshly excised mice colons. Current results demonstrate that tissue autofluorescence lifetime was sensitive to the colon anatomy and the colonocyte layer. Moreover, mice under DSS-induced colitis and 5-ASA treatments showed changes in lifetime values that were qualitatively related to inflammatory markers consistent with alterations in epithelial bioenergetics (switch between β-oxidation and aerobic glycolysis) and physical structure (colon length). This study demonstrates the ability of intraluminal FLIm to image mucosal lifetime changes in response to inflammatory treatments and supports the development of FLIm as an in vivo imaging technique for monitoring the onset, progression, and treatment of inflammatory diseases.
KW - Autofluorescence
KW - Colon dysbiosis
KW - Fluorescence lifetime imaging
KW - Inflammatory bowel disease
UR - http://www.scopus.com/inward/record.url?scp=85124976350&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124976350&partnerID=8YFLogxK
U2 - 10.3390/molecules27041317
DO - 10.3390/molecules27041317
M3 - Article
C2 - 35209104
AN - SCOPUS:85124976350
VL - 27
JO - Molecules
JF - Molecules
SN - 1420-3049
IS - 4
M1 - 1317
ER -